Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07280468 · ClinicalTrials.gov registry record · Phase 4
Endotype DIrected Treatment for OSA in Down Syndrome
A Phase 4 study, sponsored by University of Arizona.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT07280468 is a Phase 4 study that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 200 participants.
The verdict
NCT07280468, a Phase 4 study, is actively recruiting participants, sponsored by University of Arizona.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
Down syndrome is the most common genetic cause of intellectual disability. People with Down syndrome often have obstructive sleep apnea (OSA), a condition where people have difficulties with breathing while asleep. OSA can lead to poor sleep, worse quality of life, behavior problems and more difficulties with thinking ("cognitive impairment"). Current treatments for OSA in people with Down syndrome are not very effective or require surgery. The combination of 2 medications, atomoxetine and oxybutynin ("ato-oxy") is a promising treatment for OSA in people with Down syndrome, but ato-oxy does not work for everyone with Down syndrome. Similarly, oxygen is effective for OSA in some people, but does not work for everyone. This study will evaluate the use a precision medicine approach to increase the effectiveness of OSA treatment in people with Down syndrome. The study will compare two groups. In the first group, everyone will be treated with ato-oxy. In the second group, a precision medicine approach will be used to assign participants to either ato-oxy or oxygen therapy, based on the specific reasons they have OSA. The research team will enroll 200 children (age 6-17 years old) and adults with Down syndrome and OSA from five sites across the country. Half of participants will randomly receive ato-oxy while the other will receive either oxygen or ato-oxy dependent upon which treatment would be expected to work better for them. The research team will measure OSA severity, quality of life, behavior and cognition at the start of the study and after 12 months of treatment for every participant. The study will also track any treatment side effects for each treatment group.
Interventions
- DRUG Oxygen
- DRUG ato-oxy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-03-14 |
| Est. Completion | 2030-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07280468
The ClinicalTrials.gov registry entry for NCT07280468 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxygen is the first listed.
NCT07280468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07280468 about?
NCT07280468 is a clinical study titled "Endotype DIrected Treatment for OSA in Down Syndrome". Down syndrome is the most common genetic cause of intellectual disability. People with Down syndrome often have obstructive sleep apnea (OSA), a condition where people have difficulties with breathing while asleep. OSA can lead to poor sleep, worse quality of life, behavior problems and more difficu...
What is the current status of trial NCT07280468?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2026-03-14. Estimated completion is 2030-01.
What interventions are being tested in trial NCT07280468?
The interventions under investigation include: Oxygen (DRUG), ato-oxy (DRUG).
Who is sponsoring clinical trial NCT07280468?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.